Targeted Molecular Therapy Gynaecological Cancer Where are we now?
|
|
- Reginald Johns
- 5 years ago
- Views:
Transcription
1 Targeted Molecular Therapy Gynaecological Cancer Where are we now? 0 T O M D E G R E V E S U B - S P E C I A LT Y F E L L O W G Y N A E C O L O G I C A L O N C O L O G Y U N I V E R S I T Y O F P R E T O R I A Q U E E N S L A N D C E N T R E F O R G Y N A E C O L O G I C A L C A N C E R S A S G O M E E T I N G 2 5 TH O F S E P T E M B E R
2 History of Systemic Cancer Treatment 1940 s - chemotherapy agents identified Nitrogen Mustard (Mustard gas) Lymphoma s (Goodman & Gilman) Anti-Folates (Methotrexate) Acute lymphoblastic leukemia (Farber) Toxin agents interfering with all rapidly dividing cells Often accidentally discovered Hormonal therapy ICI46474 (Tamoxifen) trialed in breast cancer patients (Cole) 1998 Targeted Molecular therapy Tyrosine Kinase Inhibitors (Gleevec, Glivec ) Chronic Myelogenous Leukemia Interfering with specific targeted molecules, rather than interfering with all rapidly dividing cells (Chemotherapy)
3 Try to keep it simple. VEGF-Trap Avastin HER2 Pazopanib (Votrient ) PARP Adoptive Cell Therapy WEE1 Tyrosine Kinase PI3K/AKT/m-TOR-signaling pathway mtor Checkpoint Inhibitors & Immune Modulators VEGF Cediranib (Recentin )
4 Epithelial Ovarian Cancer 0
5 Introduction Since 1996 with the addition of paclitaxel (GOG-111), limited advances have been made in the treatment of Ovarian Cancer Toxicity has improved with carboplatin compared to cisplatin (AGO ) Decreased surgical morbidity with NACT, without improved PFS or OS (Vergote, et al ) Increased PFS and OS with intra-peritoneal chemotherapy, at increased toxicity (GOG ) Increased PFS and OS with dose-dense treatment (JGOG ) However survival rates over the past 20 years have only increased modestly It appears that a therapeutic ceiling has been reached with chemotherapy agents
6 Molecular Pathways Targets - EOC Tumour Angiogenesis PARP Inhibitors Interfering with Cell-Cycle checkpoints Folate receptors Inhibiting Insuline-Like Growth Factor (IGF) Immunotherapies
7 Tumour Angiogenesis
8 Tumour Angiogenesis Once a tumour exceeds >1mm it cannot receive adequate nutrients or oxygen from surrounding tissues. Tumour cells induce angiogenic response through VEGF pathways New blood vessels with promote growth and facilitate potential spread Angiogenesis
9 Tumour Angiogenesis - Inhibitors Anti-VEGF Bevacizumab (Avastin ) FDA approved (platinum resistant, recurrent EOC) EMA approval (first-line and recurrent EOC) Aflibercept (Zaltrap ) Tyrosine kinase inhibitors Cediranib (Recentin ) Pazopanib (Votrient ) Nintedanib (Ofev, Vargatef ) Angiopoietin inhibitor Trebananib (AMG 386) Angiogenesis
10 Bevacizumab Monoclonal antibody, binds to VEGF-receptor ligand VEGF-A Angiogenesis
11 Bevacizumab First line treatment Addition to carboplatin/paclitaxel as first line treatment and/or maintenance (12-15 months) GOG218 ICON7 Burger, et al. N Engl J Med 2011, Perren, et al. N Engl J Med 2011 Angiogenesis
12 Bevacizumab First line treatment GOG-218 (2011) ICON7 (2011) N Characteristics PFS P-value OS P- value 1,873 Stage III-IV 14.1 v.s 10.3 months < v.s months 1,528 Stage I-IV 19.0 v.s months v.s months NS NS GOG218 ICON7 Angiogenesis
13 Bevacizumab First line treatment High risk patients ICON7 (2011/2013) N Characteristics PFS P- value 502 Stage III-IV, Suboptimal debulking (>1cm residual) 16 v.s months v.s months OS P- value 0.03 Angiogenesis
14 Ongoing trials First line therapy ICON 8B Dose-dense chemotherapy and bevacizumab, High risk stage III-IV GOG 252 Preliminary results* Stage II-III, Optimal cytoreduction, n=1560 Increased toxicity in IP arms *Walker J et al. SGO 2016 Angiogenesis
15 Bevacizumab Recurrent disease Chemotherapy with bevacizumab in relapsed disease N Characteristics PFS P-value OS P-value OCEANS 484 Platinum-sensitive 12.4 v.s. 8.4 months < v.s months NS AURELIA 361 Platinum-resistant 6.7 v.s. 3.4 months < v.s months NS OCEANS AURELIA OS could be influenced by high crossover rate to bevacizumab maintenance at progression of disease Angiogenesis
16 Bevacizumab GI perforations Cannistra, et al.* Phase II trial, (n=44) Partial response rate of 15.9% GI perforation rate of 11.4% Highest rate in patients received 3 prior lines Premature termination of trial Subsequent trials: GOG-218 (n=1,873) % ICON7 (n=1,528) 1% OCEANS (n=484) 0.8% AURELIA (n=361) 2.2% *Cannistra, et al. J Clin Oncol 2007 Angiogenesis
17 Aflibercept Heterodimeric molecule, VEGF receptors 1-2 domains VEGF-Trap Decoy receptor for VEGF Coleman, et al. Phase II trial, recurrent disease (n=46) Aflibercept with docetaxel 54% objective response Gotlieb, et al. Significantly extends time to ascites drainage (55.1 v.s days) No OS benefit More grade 3-4 toxicity Angiogenesis
18 Cediranib Tyrosine kinase inhibitors Oral agent targeting VEGF 1, 2, 3 and c-kit ICON 6 (n=456), Phase III, Platinum sensitive recurrent EOC, Cediranib during and as maintenance (18 months) with platinum based chemotherapy* PFS benefit 11.4 v.s. 9.4 months (p=0.002) OS benefit 20.3 v.s months (p=0.04) Toxicity increased, but tolerable Pazopanib Oral agent targeting VEGF-, FGF-, PDGF-receptors and c-kit AGO-OVAR16 study (n=940), Phase II, 2 year maintenance therapy in first line setting (after completion of >5 cycles adjuvant chemotherapy)^ PFS benefit 17.9 v.s months (p=0.002) No difference in OS Increased Grade 3/4 Toxicity, 33% discontinued *Raja, et al. Br J Cancer 2011, ^Du Bois, et al. J Clin Oncol Off J Am Soc Clin Oncol 2014 Angiogenesis
19 Tyrosine kinase inhibitors Nintedanib Targeting VEGF-, FGF- and PDGF-receptors AGO-OVAR12, Double-blind Phase III, first line treatment with adjuvant chemotherapy (Carboplatin/Paclitaxel)* PFS benefit 18.3 v.s months (p=0.02) PFS in low risk patients 27.1 v.s months *Kristensen, et al. J Clin Oncol Off J Am Soc Clin Oncol 2011 Angiogenesis
20 Angiopoietins Inhibitor Trebananib (AMG 386) Targeting angiopoietin 1 and 2 TRINOVA-1, Phase III study (n=919), Recurrent EOC treated with trebananib and paclitaxel* PFS benefit 7.2 v.s. 5.4 months (p=<0.001) OS non-significant benefit 19.0 v.s months (p=0.19) *Monk, et al. Lancet Oncol 2014 Angiogenesis
21 Poly(adenosine diphosphate [ADP]-Ribose) Polymerase Inhibitors
22 PARP-Inhibitors PARP enzymes play role in DNA repair Inhibition causes single-strand DNA breaks, repaired by homologous recombination BRCA 1/2 Mutation-associated cancers, defective HR. Leading to double-strand DNA break during replication and subsequently cell death BRCA PARP-Inhibitors
23 Breast Cancer Tumour Suppressor Gene (BRCA) Mutation Carriers PARP Inhibition in the setting of defective BRCA protein leads to cell death BRCA 1 40% lifetime risk ovarian cancer BRCA 2 11% lifetime risk ovarian cancer 30-50% EOC harbor HR deficiency Orally available & Well Tolerated PARP Inhibitors Olaparib FDA approved (recurrent EOC, BRCA mutation and 3 prior chemotherapy regimes) EMA approval (recurrent EOC, platinum sensitive and BRCA mutation) Niraparib Talazoparib Veliparib rucaparib PARP-Inhibitors
24 PARP First Line Therapy Limited data available Ongoing trials: GOG 9923 Phase III, veliparib with carboplatin, paclitaxel and bevacizumab. SOLO1 Phase III, olaparib as maintenance (24 months) after first line carboplatin/paclitaxel, BRCA mutation PARP-Inhibitors
25 Monotherapy Recurrent EOC Olaparib maintenance after platinum based chemotherapy for platinum-sensitive EOC. Randomized, Phase II* Pre-planned sub-analysis in BRCA group No benefit of OS. However high cross-over to olaparib once relapsed *Study 19. Ledermann, et al. N Eng J Med 2012/Lancet Oncol 2014 PARP-Inhibitors
26 Ongoing trials PARP inhibitors Recurrent EOC ARIEL3 rucaparib, Phase III SOLO2 olaparib, Phase III NOVA niriparib, Phase III PARP-Inhibitors
27 Combination therapy Recurrent EOC PARPi could sensitize cells to DNA damage secondary to chemotherapy or angiogenesis inhibitors Phase II, Platinum sensitive EOC, BRCA* Olaparib combination with Carbo/Taxel, followed by olaparib maintenance v.s. chemotherapy alone Improved PFS 12.2 v.s. 9.6 months (p=0.0012) Phase II, Platinum sensitive EOC, BRCA^ Olaparib with cediranib (VEGF inhibitor) v.s. olaparib alone Improved PFS 17.7 v.s. 9 months (p=0.005) *Study 41. Oza, at al. Lancet Oncol 2015, ^Lui, et al. Lancet Oncol 2014 PARP-Inhibitors
28 Type-1 EOC Histology
29 Low-Grade Serous Carcinoma of the Ovary More indolent course, however extreme poor response rates to chemotherapy (Response rates ± 4%) Desperate need for new treatment modalities MEK-inhibitors GOG Phase II, Selumetinib in recurrent LGSC* 15% response rate, 65% stable disease MILO trial, Phase III, MEK162 with chemotherapy in recurrent/persistent LGSC - Interim analysis: Failed improvement of PFS *Farley, et al. Lancet Oncol. 2013
30 Clear-Cell Carcinoma of the Ovary Poor responses to chemotherapy 35% clear-cell ovarian cancer have PIK3CA mutation, susceptible for PI3K/AKT/m-TOR inhibitors mtor Inhibitor is being investigated Phase II, temsirolimus added to first-line chemotherapy Currently ongoing
31 Immunotherapy Immune system has prominent role in modifying clinical course of disease Anti-Cancer immune responses Infiltrating T-Cells (TILs) in ovarian cancer cells - Associated with improved survival* Manipulate the hosts cancer immune response to cause immune-mediated tumour rejection Immunotherapies have been FDA approved (Prostate cancer, Melanoma, Lymphoma) *Zhang, et al. N Engl J Med 2003
32 Immunotherapy Categories Monoclonal Antibodies Anti-angiogenic agents (Bevacizumab) Checkpoint Inhibitors & Immune Modulators Enhance pre-existing anti-cancer immune response Therapeutic Vaccines Teach immune system to recognize & target tumour cells, including memory Adoptive Cell Therapy Genetically modified immune cells, re-introduced into the patient with the goal of improving the immune system s anti-cancer response Oncolytic Viruses Modified virus that can cause tumour cells to self-destruct or Generating a greater immune responses
33 Targeted Therapy in Ovarian Cancer - Summary VEGF inhibitors Bevacizumab active in first-line and recurrent EOC (platinum sensitive and resistant) Only OS benefit in high-risk patients (post-hoc analysis) PARP inhibitors Active in EOC, specifically BRCA mutations Evidence for PFS benefit in recurrent disease Timing remains unclear Immunotherapy Promising New Kid on the Block
34 Cervix Cancer 0
35 Cervix Cancer - Introduction 4 th most common cause of cancer-related death globally Early stage disease often curable Advanced, recurrent or persistent disease often incurable Cisplatin based chemotherapy most patent However, Response rate 20-36% and Survival < 1 year* *Monk, et al. J Clin Oncol GLOBOCAN 2012
36 Target Pathways Cervix Cancer Angiogenesis Inhibitors Bevacizumab PARP- inhibitor Velaparib Immunotherapy Therapeutic Vaccines Immune Checkpoint Inhibitors Adaptive Cell Therapy
37 Bevacizumab Cervix Cancer GOG 240 Phase III (n=452), chemo-naïve patients *Tewari, et al. NEJM 2014
38 Bevacizumab GOG240 Significant improved PFS and OS PFS OS *Tewari, et al. NEJM 2014
39 Cervix Cancer - PARP inhibitor Role is Unclear Cell lines of cisplatin resistant cervix cancer has found to be PARP inhibitor sensitive* GOG-76HH - Phase I/II, advanced/recurrent/persistent cervix cancer, velaparib with cisplatin and paclitaxel (n=34) Overall response rate 34% Ongoing, Phase I/II trials investigating velaparib with topotecan or cisplatin/carbotaxel in advanced/recurrent cervix cancer. *Michels, at al. Cancer Res. 2013
40 Immunotherapy Cervix Cancer Therapeutic Vaccines Cell-mediated immunity against HPV-infected cells (Cancer cells) Phase I, ADXS11-001, pre-treated advanced/recurrent disease (n=15)* % clinical response rate Phase II, ADXS with/without cisplatin, recurrent disease (n=110)^ - Response rate 43%, No added benefit of Cisplatin Ongoing, Phase II (GOG265) Immune Checkpoint Inhibitors Two ongoing phase II studies, PD-1 and CTLA-4 inhibitors Adaptive Cell Therapy HPV - tumour infiltrating lymphocytes with chemotherapy (n=9) # - 3 patients with clinical response, lasting months *Maciag, et al. Vaccine 2009, ^Basu, et al. J Clin Oncol 2014, # Stevanovic, et al. J Clin Oncol 2015
41 Endometrial Cancer
42 Target Pathways Endometrial Cancer Hormonal Therapy Angiogenesis Inhibitors Bevacizumab Aflibercept Tyrosine Kinase Inhibitors PI3K pathway mtor inhibitors HER2 inhibitors Metformin Immunotherapy
43 Hormonal Therapy Endometrial Cancer Sole approved targeted therapy Progesterone therapy Response rate 22%* Low-grade and PR-receptor positive tumours Aromatase Inhibitors & Tamoxifen Response rates ±10%^ Cochrane review: No improved survival in advanced endometrial cancer # Large randomized trials are required *Wright, et al. Lancet 2012, ^Thigpen, et al. J Clin Oncol 2001, # Koka, et al. Cochrane Database Syst Rev 2010
44 Bevacizumab Advanced/Recurrent Endometrial cancer Phase II, Advanced or Recurrent endometrial cancer (Type 1 & 2) Carboplatin/Paclitaxel +/- bevacizumab (n=66) Increased PFS 13 v.s. 8.7 months (p=0.036) *Lorusso, et al. ASCO 2015
45 Future Perspective Targeted Therapy 0
46 Future perspectives Predictive biomarkers (genomic signatures) Bevacizumab (Gourley, et al) PARP-inhibitor (on-going ARIEL2) Combination of Targeted therapies with/without chemotherapy Immunotherapies are promising
47
Angiogenesis in Ovarian Cancer
Angiogenesis in Ovarian Cancer Dr Shibani Nicum Consultant Medical Oncologist and Lead for Gynae- Oncology Oxford University Hospitals Content 1. Epithelial Ovarian Cancer : epidemiology 2. Angiogenesis-normal
More informationCómo Incorporar la Terapia Antiangiogénica en el Cáncer de Ovario? XIV Congreso Nacional Salamanca Octubre de 2013 SESION CONTROVERSIA-1 15,45-17H
Cómo Incorporar la Terapia Antiangiogénica en el Cáncer de Ovario? XIV Congreso Nacional Salamanca Octubre de 2013 SESION CONTROVERSIA-1 15,45-17H Andres Poveda Fundación Instituto Valenciano de Oncología
More informationTable Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies
Table Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies Uterus Study N Eligibility Regimen RR (No. of Responses) Median OS Grade 3/4 Toxicities Nimeiri et al[42] Total:
More informationVirtual Journal Club. Ovarian Cancer. Reference Slides. Platinum-Sensitive Recurrent Ovarian Cancer: Making the Most of Emerging Targeted Therapies
Virtual Journal Club Ovarian Cancer Reference Slides Platinum-Sensitive Recurrent Ovarian Cancer: Making the Most of Emerging Targeted Therapies Mansoor R. Mirza, MD Copenhagen University Hospital Rigshospitalet
More information2/21/2016. Cancer Precision Medicine: A Primer. Ovarian Cancer Statistics and Standard of Care in 2015 OUTLINE. Background
Cancer Precision Medicine: A Primer Rebecca C. Arend, MD Division of Gyn Oncology OUTLINE Background Where we are Where we have been Where we are going Targeted Therapy in Ovarian Cancer How to Individualized
More informationPARP Inhibitors: Patients Selection. Dr. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau Formigal, June 23th 2016
PARP Inhibitors: Patients Selection Dr. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau Formigal, June 23th 2016 OVARIAN CANCER (OC): MULTIPLES DISEASES Different types with different behaviour
More informationCurrent Medical Oncology Approaches to Gynecologic Cancers. Mihaela Cristea, MD Associate Professor Medical Oncology
Current Medical Oncology Approaches to Gynecologic Cancers Mihaela Cristea, MD Associate Professor Medical Oncology Nothing to disclose DISCLOSURE Ovarian Cancer Objectives: a. To discuss new FDA approved
More informationNew Treatments for Early Ovarian Cancer. Jonathan Ledermann UCL Cancer Institute University College London
New Treatments for Early Ovarian Cancer Jonathan Ledermann UCL Cancer Institute University College London Lucerne Oct 213 Progression-free survival in first-line trials of platinum-based chemotherapy 1998
More informationUpdate on PARP inhibitors: opportunities and challenges in cancer therapy
Update on PARP inhibitors: opportunities and challenges in cancer therapy Vanda Salutari Unità di Ginecologia Oncologica Fondazione Policlinico Universitario A. Gemelli vanda.salutari@policlinicogemelli.it
More informationGOG-172: Survival Outcomes
CHEMOTHERAPY GOG-172: Survival Outcomes Progression-Free Survival Overall Survival Proportion Progression-Free 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 Rx Group IV IP PF Failed Total 50 160 210 63 142
More informationLate recurrent epithelial ovarian cancer
Late recurrent epithelial ovarian cancer Dominic Richards University of Cape Town and New Somerset Hospital Gynaecological Oncology Unit September 2016 LATE RECURRENT EPITHELIAL OVARIAN CANCER Background
More informationACRIN Gynecologic Committee
ACRIN Gynecologic Committee Fall Meeting 2010 ACRIN Abdominal Committee Biomarkers & Endpoints in Ovarian Cancer Trials Robert L. Coleman, MD Professor and Vice Chair, Clinical Research Department of Gynecologic
More information10/24/14. Grand Rounds in Ovarian Cancer: Standards of Care and Novel Treatment Approaches. Disclosure. Learning Objectives
10/24/14 Grand Rounds in Ovarian Cancer: Standards of Care and Novel Treatment Approaches Jessica Gahres, PA-C Memorial Sloan Kettering Cancer Center Don S. Dizon, MD Massachusetts General Hospital Cancer
More informationESMO PRECEPTORSHIP IN IMMUNO-ONCOLOGY
ESMO PRECEPTORSHIP IN IMMUNO-ONCOLOGY LUGANO, MAY 4-5, 2018 Clinical development in ovarian cancer C. Sessa, CH CONTENT Rationale for immunotherapy in ovarian cancer Clinical data with single agent immune
More informationControversies in the Management of Advanced Ovarian Cancer
안녕하세요 Controversies in the Management of Advanced Ovarian Cancer Mansoor R. Mirza Nordic Society of Gynaecological Oncology (NSGO) & Rigshospitalet Copenhagen University Hospital, Denmark Primary Debulking
More informationPARP inhibitors for breast cancer
PARP inhibitors for breast cancer Mark Robson, MD Memorial Sloan Kettering Cancer Center Agenda Mechanism of action Clinical studies Resistance mechanisms Future directions Poly (ADP-ribose) Polymerases
More informationMedicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático
Medicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático Dra. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau. Barcelona Introduction Ovarian cancer is the fifth
More informationInhibidores de PARP en cáncer de ovario
Inhibidores de PARP en cáncer de ovario Ma Pilar Barretina Ginesta Servicio Oncología Médica Hospital Universitari Dr. J. Trueta Institut Català d Oncologia Coordinación científica: Dr. Fernando Rivera
More informationPractical Guidance and Strategies for PARP Inhibition. Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy
Practical Guidance and Strategies for PARP Inhibition Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy Clinical Data Maintenance therapy : BRCA-mutated or all
More informationPrincipal changes in clinical trials involving patients with Ovarian Cancer
Verona, 18.01.2019 Principal changes in clinical trials involving patients with Ovarian Cancer Principal changes in clinical trials involving patients with Ovarian Cancer Agenda 1. Patients: Biomarker
More informationJae Kwan Lee. Division of Gynecologic Oncology Department of Obstetrics and Gynecology Korea University College of Medicine
Jae Kwan Lee Division of Gynecologic Oncology Department of Obstetrics and Gynecology Korea University College of Medicine Targeted Therapy: Categories Anti-angiogesis therapy (1) VEGF-axis dependent Monoclonal
More informationCurrent state of upfront treatment for newly diagnosed advanced ovarian cancer
Current state of upfront treatment for newly diagnosed advanced ovarian cancer Ursula Matulonis, M.D. Associate Professor of Medicine, HMS Program Leader, Medical Gyn Oncology Dana-Farber Cancer Institute
More informationFoROMe Lausanne 6 février Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV
FoROMe Lausanne 6 février 2014 Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV Epithelial Ovarian Cancer (EOC) Epidemiology Fifth most common cancer in women and forth most common
More informationNew Developments in Ovarian Cancer
New Developments in Ovarian Cancer Daniela Matei, MD Professor Gynecology Oncology Northwestern University Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Outline Recent and ongoing
More informationTarceva Trial EORTC 55041
Tarceva Trial EORTC 55041 Primary Chemotherapy Tarceva consolidation 2 years Control Patients closed / 835 Leading Participating EORTC AGO-AUSTRIA, ANZGOG, GINECO, MRC/NCIC, MANGO Randomised trial on Erlotinib
More informationA New String to the Bow in the Treatment of Advanced Ovarian Cancer Bradley J. Monk, MD, FACS, FACOG
A New String to the Bow in the Treatment of Advanced Ovarian Cancer Bradley J. Monk, MD, FACS, FACOG Arizona Oncology (US Oncology Network) Professor, Gynecologic Oncology University of Arizona and Creighton
More informationOvarian Cancer: Implications for the Pharmacist
Ovarian Cancer: Implications for the Pharmacist Megan May, Pharm.D., BCOP Objectives Describe the etiology and pathophysiology of ovarian cancer Outline the efficacy and safety of treatment options for
More informationbreast and OVARIAN cancer
breast and OVARIAN cancer DR DAVID FENNELLY CONSULTANT MEDICAL ONCOLOGIST ST VINCENT S UNIVERSITY HOSPITAL DUBLIN HOW RELEVANT IS ONCOLOGY IN MEDICINE TODAY? Cancer is the second leading cause of death
More informationGranulosa Cell Tumor Monitoring and Treatment. Outline: 1. Surgery 2. Adjuvant 3. Chemo 4. Hormonal 5. Investigational. Whole Genome Sequencing
Potential Conflicts of Interest capped at a level befitting an academic role Lo B. Serving Two Masters 2010;362:669-671 Granulosa Cell Tumor Monitoring and Treatment Richard T. Penson, MD, MRCP Clinical
More informationNCCN Guidelines for Ovarian Cancer V Meeting on 11/15/17
OV-1 External request: Submission from Vermillion/ASPiRA Laboratories to consider: Inclusion of the following recommendation in the workup for suspected ovarian cancer: OVA1 and/or Multivariate Index Assay
More informationGOG212: Taxane Maintenance
GOG212: Taxane Maintenance Epithelial Ovarian or Primary Peritoneal Cancer Optimal or Suboptimal Cytoreduction Clinical C with normal CA125, no symptoms, normal CT Primary Carboplatin and Paclitaxel (or
More informationTargeted therapy for gynecologic cancers: Toward the era of precision medicine
DOI: 10.1002/ijgo.12620 FIGO CANCER REPORT 2018 Targeted therapy for gynecologic cancers: Toward the era of precision medicine Partha Basu 1 Asima Mukhopadhyay 2 Ikuo Konishi 3, * 1 Screening Group, Early
More informationUpdate on PARP inhibitors
Professor of Medicine Harvard Medical School Boston MA Update on PARP inhibitors Ursula Matulonis, M.D. Chief, Division of Gynecologic Oncology Brock-Wilson Family Chair Dana-Farber Cancer Institute History
More informationESMO SUMMIT AFRICA. Latest evidence and current standard of care in advanced ovarian cancer. C.Sessa. Cape Town February 2018
ESMO SUMMIT AFRICA Latest evidence and current standard of care in advanced ovarian cancer C.Sessa IOSI, Bellinzona, CH Cape Town 14-16 February 2018 CONFLICT OF INTEREST DISCLOSURE None Ovarian carcinoma
More informationTreatment of Recurrent Ovarian Cancer
Treatment of Recurrent Ovarian Cancer Mihaela Cristea, MD Associate Professor Medical Oncology, City of Hope November 11, 2016 No disclosures Financial Disclosure Epithelial Ovarian Cancer Subtypes and
More informationBrian T Burgess, DO, PhD, GYN Oncology Fellow Rachel W. Miller, MD, GYN Oncology
Brian T Burgess, DO, PhD, GYN Oncology Fellow Rachel W. Miller, MD, GYN Oncology Epithelial Ovarian Cancer - Standard Current Treatment: Surgery with De-bulking + Platinum-Taxane based Chemotherapy - No
More informationPROSTATE CANCER HORMONE THERAPY AND BEYOND. Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute
PROSTATE CANCER HORMONE THERAPY AND BEYOND Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute Disclosures I am a Consultant for Bayer and Sanofi-Aventis
More informationDieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
What is hot in breast cancer brain metastases? Dieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands 8th Annual Brain Metastases Research and Emerging Therapy
More informationTHE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network THE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum
More informationOverall survival results of ICON6: a trial of chemotherapy and cediranib in relapsed ovarian cancer
Overall survival results of ICON6: a trial of chemotherapy and in relapsed ovarian cancer Ledermann JA, Embleton AC, Perren T, Jayson GC, Rustin GJS, Kaye SB, Hirte HW, Oza AM, Vaughan MM, Friedlander
More information6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
More informationIntraperitoneal chemotherapy: where are we going? A. Gadducci Pisa
Intraperitoneal chemotherapy: where are we going? A. Gadducci Pisa Intraperitoneal Chemotherapy (IP) in advanced ovarian cancer (EOC): Rationale The spread of disease is often limited to the peritoneal
More informationTargeting angiogenesis: vascular endothelial growth factor and related signaling pathways
Review Article Targeting angiogenesis: vascular endothelial growth factor and related signaling pathways Amanda L. Jackson 1, Sara Madison Davenport 2, Thomas J. Herzog 3, Robert L. Coleman 4 1 Division
More informationLynparza. Lynparza (olaparib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.52 Subject: Lynparza Page: 1 of 4 Last Review Date: September 15, 2017 Lynparza Description Lynparza
More informationWhere Are Anti-Angiogenic Agents Positioned Within Cancer Care Guidelines?
Introduction Additionally, other anti-angiogenic drugs, including sorafenib, sunitinib, axitinib, pazopanib, vandetanib, The development and subsequent use of drugs for treating cancer cabozantinib, and
More informationNational Horizon Scanning Centre. Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer. December 2007
Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer December 2007 This technology summary is based on information available at the time of research and a limited literature
More informationFrom Research to Practice: What s New in Gynecologic Cancers?
From Research to Practice: What s New in Gynecologic Cancers? David Warshal, M.D. Head, Division of Gynecologic Oncology MD Anderson Cooper Cancer Institute Associate Professor of Obstetrics and Gynecology
More informationThe Role of PARP Inhibitors in Ovarian Cancer: An Emerging Picture
The Role of PARP Inhibitors in Ovarian Cancer: An Emerging Picture This satellite symposium took place on 10 th September 2017 as part of the European Society for Medical Oncology (ESMO) Congress in Madrid,
More informationPractice of Medicine-1 Ovarian Cancer Clinical Correlation
Practice of Medicine-1 Ovarian Cancer Clinical Correlation Amir A. Jazaeri, M.D. Assistant Professor, Division of Gynecologic Oncology American Cancer Society Female Cancers 2000 Statistics Reprinted by
More informationCarcinosarcoma Trial rial in s a in rare malign rare mali ancy
Carcinosarcoma Trials in a rare malignancy BACKGROUND Rare and highly aggressive epithelial malignancies Biphasic tumors with epithelial and mesenchymal components Uterine carcinomas (UCS) uncommon with
More informationCarol Davila University of Medicine and Pharmacy, Bucharest, Romania b
Mædica - a Journal of Clinical Medicine MAEDICA a Journal of Clinical Medicine 2015; 10(4): 376-381 STATE OF THE ART Antiangiogenic Treatment in Ovarian Cancer in the Era of Evidenced-Based Medicine Oana
More informationClinical Trials. Ovarian Cancer
1.0 0.8 0.6 0.4 0.2 0.0 < 65 years old 65 years old Events Censored Total 128 56 184 73 35 108 0 12 24 36 48 60 72 84 27-10-2012 Ovarian Cancer Stuart M. Lichtman, MD Attending Physician 65+ Clinical Geriatric
More informationCERVICAL/VULVAR CANCER CLINICAL TRIALS
CERVICAL/VULVAR CANCER CLINICAL TRIALS ALL-COMERS Primary Treatment Locally Advanced Recurrent Cervical GTFB (07-0935) TISSUE BANK ALL GYN TISSUE ETCTN (Phase II) (17-0458) LAO-MD017/#10010 Phase II Study
More informationProgress Update June 2017 Lay Summary Funding: $6,000,000 Grant Funded: July 2015 Dream Team Members Dream Team Leader:
SU2C -Ovarian Cancer Research Fund Alliance-National Ovarian Cancer Coalition Dream Team Translational Research Grant: DNA Repair Therapies for Ovarian Cancer AND SU2C Catalyst Merck-Supported Supplemental
More informationNew targets in endometrial and ovarian cancer
New targets in endometrial and ovarian cancer SAMO Interdisciplinary Workshop on Gynecologic Tumors Luzern, January 16-17, 2016 C. Sessa IOSI Bellinzona Outline New targets in ovarian cancer - Cell cycle
More informationNintedanib in Oncology Backgrounder
For media outside the US, UK and Canada only Nintedanib in Oncology Backgrounder 1. What is nintedanib? 2. How does nintedanib work? 3. Data overview 4. Additional clinical data 5. Nintedanib approval
More informationOVARIAN CANCER CLINICAL TRIALS
OVARIAN CANCER CLINICAL TRIALS FRONT-LINE THERAPIES STG III, IV PHASE 3 GOG 3015/Roche YO39523 (16-2745) Carbo/Taxol/Bev/Atezolizumab ECOG 0-2 Allows for primary cytoreductive surgery or interval debulking
More informationLynparza. Lynparza (olaparib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.52 Subject: Lynparza Page: 1 of 5 Last Review Date: March 16, 2018 Lynparza Description Lynparza (olaparib)
More informationOverview and future horizons of PARP inhibitors in BRCAassociated. Judith Balmaña
Overview and future horizons of PARP inhibitors in BRCAassociated breast cancer Judith Balmaña PARP inhibitors: Mechanism of action Clinical development: Monotherapy In combination with chemotherapy Ongoing
More informationBiomarker for Response and Resistance in Ovarian Cancer
2016 대한부인종양학회제 31 차춘계학술대회 New Trends in Translational Research Biomarker for Response and Resistance in Ovarian Cancer Shin-Wha Lee, M.D., Ph.D. Department of Obstetrics and Gynecology ASAN Medical Center
More informationBreakfast with Professor Advances in ovarian cancer first-line treatment : The role of anti angiogenics
Breakfast with Professor Advances in ovarian cancer first-line treatment : The role of anti angiogenics CLAUDIO CALAZAN Oncologia D Or Oncologistas Associados First-line treatment : The role of anti angiogenics
More informationRicombinazione omologa nel carcinoma ovarico: BRCA e oltre. F. Raspagliesi MD
Ricombinazione omologa nel carcinoma ovarico: BRCA e oltre F. Raspagliesi MD raspagliesi@istitutotumori.mi.it BRCA molecular signature in ovarian cancer In a pooled analysis of 26 observational studies
More informationThe next steps in improving the outcomes of advanced ovarian cancer
The next steps in improving the outcomes of advanced ovarian cancer Worldwide ovarian cancer affects over 200,000 women per year. Overall survival rates are poor due to two predominate reasons. First,
More informationImmune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group
Immune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group Results of Phase II Study of Durvalumab and Tremelimumab in recurrent clear cell ovarian cancer Trial
More informationExpert Call Innovation in Ovarian Cancer Hosted by John Sonnier, William Blair. December 13, 2016
Expert Call Innovation in Ovarian Cancer Hosted by John Sonnier, William Blair December 13, 2016 1 Forward-Looking Statements This presentation includes forward-looking statements based on management's
More informationFuture Perspectives in mpca. Michel Ducreux, MD, PhD Gustave Roussy Villejuif, France
Future Perspectives in mpca Michel Ducreux, MD, PhD Gustave Roussy Villejuif, France Number of Novel Therapies and Targets in Pancreatic Cancer Are Expanding Garrido-Laguna I, et al. Nat Rev Clin Oncol.
More informationTriple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008
Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008 Triple Negative Breast Cancer 15% 25% Triple Negative 20% HER2+ ER+ Low Grade
More informationOvarian Cancer: New insights into biology and treatment
Ovarian Cancer: New insights into biology and treatment 2018 Master Class Course Ursula A. Matulonis, MD Director, Gynecologic Oncology Brock-Wilson Family Chair Dana-Farber Cancer Institute Professor
More informationThe Ohio State University Approach to Advanced Ovarian Cancer Korean Society of Gynecologic Oncology
The Ohio State University Approach to Advanced Ovarian Cancer Korean Society of Gynecologic Oncology April 26, 2013 Larry J. Copeland M.D. Thank You for Your Friendship! 1982 1996 2013 The Ohio State University
More informationCurrent options and future opportunities in platinum-resistant ovarian cancer. Aknar Calabrich AMO
Current options and future opportunities in platinum-resistant ovarian cancer Aknar Calabrich AMO LACOG CONFERENCE 2013 Current options and future opportunities in platinum-resistant ovarian cancer Aknar
More informationTREATMENT FOR RELAPSING PLATINUM SENSITIVE EPITHELIAL OVARIAN CANCER
TREATMENT FOR RELAPSING PLATINUM SENSITIVE EPITHELIAL OVARIAN CANCER Sandro Pignata, MD, PhD Sabrina Chiara Cecere, MD Uro-Gynecological Department, Division of Medical Oncology, IRCCS National Cancer
More informationVisiting Professors. Clinical Investigators Review Key Publications and Current Cases in Gynecologic Oncology
Visiting Professors Clinical Investigators Review Key Publications and Current Cases in Gynecologic Oncology C M E I N F O R M A T I O N TARGET AUDIENCE This activity is intended for gynecologic and medical
More informationASCO- GYN Abstracts 8/3/2011. Susana Campos, MD, MPH. Boston Mass. Prevention. Maintenance. Recurrent Disease.
ASCO- GYN- 2011 Susana Campos, MD, MPH Dana Farber Cancer Institute Boston Mass Prevention Maintenance Recurrent Disease Abstracts 5001: Effect of screening on ovarian cancer mortality in the Prostate,
More informationSOLO-1. Dott.ssa Elisabetta Sanna U.O.C. Ginecologia Oncologica- AOB Cagliari Direttore: Dott. Antonio Macciò
SOLO-1 maintenance therapy in patients with newly diagnosed advanced ovarian cancer following platinum-based chemotherapy Dott.ssa Elisabetta Sanna U.O.C. Ginecologia Oncologica- AOB Cagliari Direttore:
More informationIn 2017, an estimated 22,240 women will
OVARIAN CANCER Ovarian cancer remains the most deadly gynecologic malignancy in the United States. What are the practice implications of recent research results on screening, neoadjuvant chemotherapy,
More informationGYNECOLOGICAL CANCERS
SAMO FoROMe Post ESMO 17 th October 2014, Bern GYNECOLOGICAL CANCERS Cristiana Sessa Oncology Institute of Southern Switzerland Bellinzona CONTENT Antiangiogenics in cervical cancer Antiangiogenics and
More informationJemal A, Siegel R, Ward E, et al: Cancer statistics, CA: Cancer J Clin 59(4):225-49, 2009
Ovarian cancer 2010-22,500 cases diagnosed per year in the United States and 16,500 deaths per year1. - Most patients are diagnosed in late stages; no screening test exists. - Pathology: 4 different types
More informationMedical Therapies in Ovarian Cancer The Arabic Perspectives. Mezghani Bassem -Tunisia
Tunisian Health System: Social Welfare with a Public insurance for all citizens including Indigent persons. (± Additional private insurance) Choice: Public Hospital/Private Clinics (Indigents Public H)
More informationBY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Cancer is a group of more than 100 different diseases that are characterized by uncontrolled cellular growth,
More informationBases biológicas del cáncer de ovario en el siglo XXI
Bases biológicas del cáncer de ovario en el siglo XXI Iñigo Espinosa, M.D. Clínica Universidad de Navarra Epithelial Ovarian Tumors WHO 1973-2014 Serous Mucinous Endometrioid Clear cell Transitional Squamous
More informationDr. Josep M. Del Campo Clínica Diagonal. Barcelona
Dr. Josep M. Del Campo Clínica Diagonal. Barcelona Nuevas Oportunidades en Cáncer de Ovario Cancer de Ovario: Es una enfermedad única? Cáncer de Ovario: Tratamiento actual Tratamiento inicial: sin cambios
More informationRTWG - Carcinosarcoma. Max Parmar, Jane Bryce, Andreas Poveda, Amit Oza
RTWG - Carcinosarcoma Max Parmar, Jane Bryce, Andreas Poveda, Amit Oza Overview Background Questions urgent and timely investigations? Proposed Approach Regulatory Solutions Output Carcinosarcomas Background
More informationPrecision Genetic Testing in Cancer Treatment and Prognosis
Precision Genetic Testing in Cancer Treatment and Prognosis Deborah Cragun, PhD, MS, CGC Genetic Counseling Graduate Program Director University of South Florida Case #1 Diana is a 47 year old cancer patient
More informationInhibidores de PARP Una realidad? dónde y cuando?
Inhibidores de PARP Una realidad? dónde y cuando? Alberto Ocana Hospital Universitario Albacete Centro Regional Investigaciones Biomédicas CIC-Salamanca DNA repair mechanisms DNA is continually exposed
More informationEpithelial Ovarian Cancer Surgical and Systemic treatment
Epithelial Ovarian Cancer Surgical and Systemic treatment Jan B. Vermorken, MD, PhD Department of Medical Oncology Antwerp University Hospital Edegem, Belgium 4 th ESO-ESMO Masterclass in Clinical Oncology
More informationNew Developments in Cancer Treatment. Ian Rabinowitz MD
New Developments in Cancer Treatment Ian Rabinowitz MD Treatment Outline Angiogenesis inhibition Targeted therapy Immunotherapy Personalization of therapy Genomics and cancer Stem cells and cancer Angiogenesis
More informationOVAIRES PROTOCOLES PTES PHASE DESCRIPTION
SERVICE DE GYNÉCOLOGIE-ONCOLOGIE PROTOCOLES EN RECRUTEMENT OVAIRES PROTOCOLES PTES PHASE DESCRIPTION OV25 DP/GSO/GSO/FG II PRÉVENTION A Randomized Phase II Double-Blind Placebo-Controlled Trials of Acetylsalicylic
More informationGCIG Rare Tumour Brainstorming Day
GCIG Rare Tumour Brainstorming Day Relatively (Not So) Rare Tumours Adenocarcinoma of Cervix Keiichi Fujiwara, Ros Glasspool Benedicte Votan, Jim Paul Aim of the Day To develop at least one clinical trial
More informationMedia Release. Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer. Basel, 08 February 2011
Media Release Basel, 08 February 2011 Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer Avastin study in recurrent, platinum-sensitive ovarian cancer showed women lived
More informationOvarian Cancer. Georgia McCann, MD. Division of Gynecologic Oncology
Ovarian Cancer Georgia McCann, MD Division of Gynecologic Oncology Myth: Ovarian cancer is a silent killer Non-specific Abdominal pain, discomfort Bloating, back pain Urinary urgency Constipation Tiredness
More informationsymposium article Optimal primary therapy of ovarian cancer M. A. Bookman* introduction symposium article
Annals of Oncology 27 (Supplement 1): i58 i62, 2016 doi:10.1093/annonc/mdw088 Optimal primary therapy of ovarian cancer M. A. Bookman* Arizona Oncology and US Oncology Research, Tucson, AZ, USA Background:
More informationPROGNOSTIC FACTORS AND FIRST LINE CHEMOTHERAPY IN AOC
PROGNOSTIC FACTORS AND FIRST LINE CHEMOTHERAPY IN AOC Giorgia Mangili RUF ginecologia oncologica medica IRCCS San Raffaele Milano mangili.giorgia@hsr.it STANDARD CHEMOTHERAPY The standard chemotherapy
More informationPARP inibitori nel trattamento del carcinoma mammario metastatico: recenti successi e prospettive future.
PARP inibitori nel trattamento del carcinoma mammario metastatico: recenti successi e prospettive future. Dr.ssa Angela Toss Centro Oncologico Modenese Università di Modena e Reggio Emilia MECHANISMS OF
More informationTHE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER. Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium
THE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium DISCLAIMER Please note: The views expressed within this presentation
More informationThe OReO Study. Study design & Protocol Study design Key Inclusion criteria Patient population Recruitment and retention tools
The OReO Study A Phase IIIb, Randomised, Double-blind, Placebo-controlled, multi-centre Study of Olaparib Maintenance Re-treatment in Patients with Epithelial Ovarian Cancer Previously treated with a and
More informationMultimedia Appendix 6 Educational Materials Table of Contents. Intervention Educational Materials Audio Script (version 1)
Multimedia Appendix 6 Educational Materials Table of Contents Intervention Educational Materials... 1 Audio Script (version 1)... 1 Text (version 1)... 5 Slides (version 1)... 17 Audio Script (version
More informationLo stato dell arte nel carcinoma ovarico: Il Trattamento Medico
Azienda Ospedaliera Universitaria Policlinco «P.Giaccone» Palermo UOC Oncologia Medica Direttore Prof. Antonio Russo Lo stato dell arte nel carcinoma ovarico: Il Trattamento Medico Lorena Incorvaia Dichiarazione
More informationJosé Baselga, MD, PhD
i n t e r v i e w José Baselga, MD, PhD Dr Baselga is Physician-in-Chief at Memorial Sloan-Kettering Cancer Center in New York, New York. Tracks 1-15 Track 1 Track 2 Track 3 Track 4 Track 5 Track 6 Track
More informationImmunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game?
Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game? Sylvie NEGRIER MD, PhD Centre Léon Bérard, Lyon Université Lyon I IMMUNOTHERAPY: A LONG AND WIDING ROAD! WHERE
More informationSystemic Therapy of Epithelial Ovarian Cancer. Jan B. Vermorken, MD, PhD Department of Medical Oncology Antwerp University Hospital Edegem, Belgium
Systemic Therapy of Epithelial Ovarian Cancer Jan B. Vermorken, MD, PhD Department of Medical Oncology Antwerp University Hospital Edegem, Belgium 5th ESO-ESMO Eastern European and Balkan Region Masterclass
More information